SE452158B - Derivat av 1,2,4-oxadiazolin-5-on, sett for deras framstellning och farmaceutiska beredningar innehallande dem - Google Patents

Derivat av 1,2,4-oxadiazolin-5-on, sett for deras framstellning och farmaceutiska beredningar innehallande dem

Info

Publication number: SE452158B
Authority: SE; Sweden
Prior art keywords: group; alkyl; phenyl; groups; alkoxy
Prior art date: 1979-10-11

Application number

SE8007025A

Other languages

English (en)

Swedish (sv)

Other versions

SE8007025L (sv

Inventor

K Takacs

I Kiss

A Simay

Nagy P Literati

M Hetyey

M Ecsery

L Szekeres

G Papp

S Viragh

E Udvardy

Original Assignee

Chinoin Gyogyszer Es Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-10-11

Filing date

1980-10-07

Publication date

1987-11-16

1980-10-07 Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet

1981-04-12 Publication of SE8007025L publication Critical patent/SE8007025L/xx

1987-11-16 Publication of SE452158B publication Critical patent/SE452158B/sv

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical class O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 title claims description 4
238000002360 preparation method Methods 0.000 title description 3
-1 6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl Chemical group 0.000 claims description 34
150000001875 compounds Chemical class 0.000 claims description 33
238000000034 method Methods 0.000 claims description 24
125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 12
239000003960 organic solvent Substances 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
150000008044 alkali metal hydroxides Chemical class 0.000 claims description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 15
125000003545 alkoxy group Chemical group 0.000 claims 15
125000005843 halogen group Chemical group 0.000 claims 13
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
125000000217 alkyl group Chemical group 0.000 claims 4
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
125000004093 cyano group Chemical group *C#N 0.000 claims 3
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
239000004927 clay Substances 0.000 claims 1
125000000753 cycloalkyl group Chemical group 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
125000002560 nitrile group Chemical group 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical class C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 21
229910052739 hydrogen Inorganic materials 0.000 description 21
238000002844 melting Methods 0.000 description 20
230000008018 melting Effects 0.000 description 20
238000001953 recrystallisation Methods 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 17
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
239000000499 gel Substances 0.000 description 9
125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 8
CEIXWJHURKEBMQ-UHFFFAOYSA-N Heliamine Chemical compound C1CNCC2=C1C=C(OC)C(OC)=C2 CEIXWJHURKEBMQ-UHFFFAOYSA-N 0.000 description 8
230000008859 change Effects 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
238000001704 evaporation Methods 0.000 description 7
239000002904 solvent Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
239000002585 base Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
HMYJLVDKPJHJCF-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNC(C)C2=C1C=C(OC)C(OC)=C2 HMYJLVDKPJHJCF-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
230000017531 blood circulation Effects 0.000 description 4
125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 4
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
UVGYAOQHGGLHHV-UHFFFAOYSA-N 2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)acetonitrile Chemical compound C1CNC(CC#N)C2=C1C=C(OC)C(OC)=C2 UVGYAOQHGGLHHV-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
230000003288 anthiarrhythmic effect Effects 0.000 description 2
230000003257 anti-anginal effect Effects 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
206010061592 cardiac fibrillation Diseases 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
238000001816 cooling Methods 0.000 description 2
210000001105 femoral artery Anatomy 0.000 description 2
230000002600 fibrillogenic effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229960004194 lidocaine Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
229960001789 papaverine Drugs 0.000 description 2
230000036581 peripheral resistance Effects 0.000 description 2
239000000376 reactant Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
ZURLOZJIDLZAOI-UHFFFAOYSA-N 3,4-dihydropyrazol-5-one Chemical compound O=C1CCN=N1 ZURLOZJIDLZAOI-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
101000637249 Homo sapiens Nexilin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102100031801 Nexilin Human genes 0.000 description 1
241000700159 Rattus Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
239000003218 coronary vasodilator agent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000004217 heart function Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960001404 quinidine Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

SE8007025A 1979-10-11 1980-10-07 Derivat av 1,2,4-oxadiazolin-5-on, sett for deras framstellning och farmaceutiska beredningar innehallande dem SE452158B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU79CI1973A HU179951B (en)	1979-10-11	1979-10-11	Process for preparing 1,2,4-oxadiazolin-5-one derivatives and pharmaceutical compositions containing thereof

Publications (2)

Publication Number	Publication Date
SE8007025L SE8007025L (sv)	1981-04-12
SE452158B true SE452158B (sv)	1987-11-16

Family

ID=10994764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8007025A SE452158B (sv)	1979-10-11	1980-10-07	Derivat av 1,2,4-oxadiazolin-5-on, sett for deras framstellning och farmaceutiska beredningar innehallande dem

Country Status (23)

Country	Link
US (1)	US4365064A (it)
JP (1)	JPS5661375A (it)
AT (1)	AT375369B (it)
BE (1)	BE885633A (it)
CA (1)	CA1154019A (it)
CH (1)	CH649547A5 (it)
CS (1)	CS241032B2 (it)
DD (1)	DD153550A5 (it)
DE (1)	DE3037432A1 (it)
DK (1)	DK149854C (it)
ES (1)	ES495819A0 (it)
FI (2)	FI71318C (it)
FR (1)	FR2467203A1 (it)
GB (1)	GB2059967B (it)
HU (1)	HU179951B (it)
IL (1)	IL61175A (it)
IT (1)	IT1129305B (it)
NL (1)	NL8005586A (it)
NO (1)	NO154795C (it)
PL (3)	PL131375B1 (it)
SE (1)	SE452158B (it)
SU (1)	SU1087519A1 (it)
YU (1)	YU41738B (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU180708B (en) *	1979-10-11	1983-04-29	Chinoin Gyogyszer Es Vegyeszet	Process for preparing new 1,2,4-oxadiazine derivatives
CZ20023110A3 (cs) *	2000-03-20	2003-02-12	N-Gene Research Laboratories Inc.	Deriváty amidoximu propenkarboxylové kyseliny, způsob jejich přípravy a farmaceutické přípravky je obsahující
US10118918B2 (en)	2012-12-21	2018-11-06	Epizyme, Inc.	PRMT5 inhibitors and uses thereof
CA2899363A1 (en)	2012-12-21	2014-06-26	Epizyme, Inc.	Prmt5 inhibitors and uses thereof
WO2014100695A1 (en)	2012-12-21	2014-06-26	Epizyme, Inc.	Prmt5 inhibitors and uses thereof
CA2894130A1 (en)	2012-12-21	2014-06-26	Epizyme, Inc.	Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
PT2935222T (pt)	2012-12-21	2018-12-10	Epizyme Inc	Inibidores de prmt5 e seus usos
AU2015301196A1 (en)	2014-08-04	2017-01-12	Epizyme, Inc.	PRMT5 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1529700A (fr) *	1967-04-11	1968-06-21	Dausse Sa Lab	Tertioaminoalcoyl oxadiazolinones et leur procédé de préparation
FR1575552A (it) *	1967-12-07	1969-07-25
US4038279A (en) *	1972-12-23	1977-07-26	Boehringer Ingelheim Gmbh	N-aryl-n'-(phenyl-or phenoxy-alkyl)-piperazines and salts thereof
US3994891A (en) *	1974-12-20	1976-11-30	Armour Pharmaceutical Company	Tetrahydroisoquinoline compounds
US4187220A (en) *	1977-08-30	1980-02-05	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T.	New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU180708B (en) *	1979-10-11	1983-04-29	Chinoin Gyogyszer Es Vegyeszet	Process for preparing new 1,2,4-oxadiazine derivatives

1979
- 1979-10-11 HU HU79CI1973A patent/HU179951B/hu not_active IP Right Cessation
1980
- 1980-09-30 IL IL61175A patent/IL61175A/xx unknown
- 1980-10-03 DE DE19803037432 patent/DE3037432A1/de not_active Withdrawn
- 1980-10-06 CS CS806737A patent/CS241032B2/cs unknown
- 1980-10-07 SE SE8007025A patent/SE452158B/sv not_active IP Right Cessation
- 1980-10-09 FR FR8021624A patent/FR2467203A1/fr active Granted
- 1980-10-09 IT IT68555/80A patent/IT1129305B/it active
- 1980-10-09 AT AT0501380A patent/AT375369B/de not_active IP Right Cessation
- 1980-10-09 JP JP14066880A patent/JPS5661375A/ja active Pending
- 1980-10-09 NL NL8005586A patent/NL8005586A/nl not_active Application Discontinuation
- 1980-10-10 FI FI803219A patent/FI71318C/fi not_active IP Right Cessation
- 1980-10-10 SU SU802993201A patent/SU1087519A1/ru active
- 1980-10-10 GB GB8032828A patent/GB2059967B/en not_active Expired
- 1980-10-10 NO NO803044A patent/NO154795C/no unknown
- 1980-10-10 CH CH7599/80A patent/CH649547A5/de not_active IP Right Cessation
- 1980-10-10 BE BE0/202406A patent/BE885633A/fr not_active IP Right Cessation
- 1980-10-10 DK DK429780A patent/DK149854C/da not_active IP Right Cessation
- 1980-10-10 CA CA000362217A patent/CA1154019A/en not_active Expired
- 1980-10-10 DD DD80224478A patent/DD153550A5/de not_active IP Right Cessation
- 1980-10-10 YU YU2594/80A patent/YU41738B/xx unknown
- 1980-10-10 PL PL1980227209A patent/PL131375B1/pl unknown
- 1980-10-10 PL PL1980232293A patent/PL132131B1/pl unknown
- 1980-10-10 FI FI803220A patent/FI71932C/fi not_active IP Right Cessation
- 1980-10-10 ES ES495819A patent/ES495819A0/es active Granted
- 1980-10-10 PL PL1980232292A patent/PL131451B1/pl unknown
- 1980-10-14 US US06/196,583 patent/US4365064A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ATA501380A (de)	1983-12-15
PL131451B1 (en)	1984-11-30
FI71932B (fi)	1986-11-28
NO803044L (no)	1981-04-13
US4365064A (en)	1982-12-21
HU179951B (en)	1983-01-28
SE8007025L (sv)	1981-04-12
DK429780A (da)	1981-04-12
PL232293A1 (it)	1982-04-26
FR2467203B1 (it)	1985-03-22
IL61175A (en)	1984-08-31
PL131375B1 (en)	1984-11-30
PL232292A1 (it)	1982-04-26
IL61175A0 (en)	1980-11-30
DK149854C (da)	1987-04-21
YU259480A (en)	1984-02-29
NO154795C (no)	1986-12-29
NO154795B (no)	1986-09-15
IT1129305B (it)	1986-06-04
DK149854B (da)	1986-10-13
GB2059967A (en)	1981-04-29
DD153550A5 (de)	1982-01-13
FI803220L (fi)	1981-04-12
CA1154019A (en)	1983-09-20
FI71932C (fi)	1987-03-09
FI803219L (fi)	1981-04-12
CS673780A2 (en)	1985-06-13
PL227209A1 (it)	1981-12-11
YU41738B (en)	1987-12-31
JPS5661375A (en)	1981-05-26
BE885633A (fr)	1981-02-02
SU1087519A1 (ru)	1984-04-23
FI71318B (fi)	1986-09-09
ES8106725A1 (es)	1981-09-16
GB2059967B (en)	1983-06-02
FR2467203A1 (fr)	1981-04-17
CS241032B2 (en)	1986-03-13
AT375369B (de)	1984-07-25
PL132131B1 (en)	1985-02-28
DE3037432A1 (de)	1981-05-27
CH649547A5 (de)	1985-05-31
NL8005586A (nl)	1981-04-14
ES495819A0 (es)	1981-09-16
IT8068555A0 (it)	1980-10-09
FI71318C (fi)	1986-12-19

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8007025-3

Effective date: 19940510

Format of ref document f/p: F

Publication	Publication Date	Title
JP2651043B2 (ja)	1997-09-10	ジフェニルメチルピペラジン誘導体
US4330542A (en)	1982-05-18	N(Sulfonyl)anilines for treating angina pectoris
PL90322B1 (it)	1977-01-31
AU665172B2 (en)	1995-12-21	1,4-disubstituted piperazines
JPH0428269B2 (it)	1992-05-13
SE452158B (sv)	1987-11-16	Derivat av 1,2,4-oxadiazolin-5-on, sett for deras framstellning och farmaceutiska beredningar innehallande dem
SE461219B (sv)	1990-01-22	1,5-bensotiazepiner med kardiovaskulaer anvaendbarhet, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner som innehaaller dem
EP0104614B1 (en)	1986-12-30	Phenylpiperazine derivatives and process for producing the same
SE468560B (sv)	1993-02-08	1-(hydroxistyryl)-5h-2,3-bensodiazepinderivat, foerfarande foer deras framstaellning samt farmaceutiska kompositioner innehaallande desamma
US4782069A (en)	1988-11-01	1,4-Dihydropiridines and their use as antithrombotic drugs
CH640227A5 (de)	1983-12-30	Aminoalkoxyphenyl-derivate.
SK158692A3 (en)	1995-03-08	2-amino-5-cyano-1,4-dihydropyridines, method of their preparation and their use in medicines
SK2722002A3 (en)	2002-07-02	Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia
DK150197B (da)	1987-01-05	Analogifremgangsmaade til fremstilling af 2-substituerede 1-aminoalkoximino-cycloalkaner eller et syreadditionssalt eller quaternaert ammoniumderivat deraf
US3244701A (en)	1966-04-05	Butadiene-carboxylic acid piperazides
US4948812A (en)	1990-08-14	1-phenoxy-3-amino-2-propanols use thereof
US4351837A (en)	1982-09-28	1,4-Dihydropyridine-3,5-dicarboxylate-4-carboxamide compounds, compositions containing same and method of using same
PL84224B1 (it)	1976-03-31
IL28197A (en)	1971-05-26	Piperazine derivatives and their manufacture
US2570286A (en)	1951-10-09	Tertiary-amino-2-aryl-2-(4-quinolyl) alkane-nitriles and their preparation
US4866176A (en)	1989-09-12	8-Piperazinyl-1,7-naphthyridine derivative having pharmaceutical activity
US2803627A (en)	1957-08-20	Therapeutic quinoline compounds
JPS63112577A (ja)	1988-05-17	１―［３―（２―ジアルキルアミノエトキシ）―２―チエニル］―３―フェニル―１―プロパノン及びそれらの酸付加塩，それらの製法及びそれらを含有する抗不整脈剤
DD268940A5 (de)	1989-06-14	Verfahren zur herstellung von neuen 3-(hydroxymethyl)-isochinolin-derivaten
SE448234B (sv)	1987-02-02	Derivat av 1,2,4-oxadiazin, sett for deras framstellning och farmaceutiska beredningar innehallande dem